Glenmede Trust’s Amicus Therapeutics FOLD Stock Holding History

Glenmede Trust’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,050	Closed	-$14	–	3105
2019 Q1	$14	Buy	+1,050	New	+$12.8K	﹤0.01%	2237
2015 Q2	–	Sell	-53,019	Closed	-$576K	–	2710
2015 Q1	$576K	Buy	+53,019	New	+$467K	﹤0.01%	905

Other funds holding FOLD

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Glenmede Trust's FOLD Position: Q2 2019 in Review

Glenmede Trust sold out of Amicus Therapeutics (FOLD) in Q2 2019, closing a stake of 1,050 shares — an estimated $14 sold.

Glenmede Trust first reported a position in FOLD in Q1 2015 and held it in 2 quarters. The position peaked at $576K in Q1 2015. 206 funds tracked by Wall St. Rank hold FOLD as of Q2 2019.

Glenmede Trust reported no remaining Amicus Therapeutics position as of Q2 2019 after selling out during the quarter.
Glenmede Trust sold 1,050 Amicus Therapeutics shares in Q2 2019, an estimated $14.
Glenmede Trust first reported a position in Amicus Therapeutics in Q1 2015 and held it in 2 quarters.
Glenmede Trust's Amicus Therapeutics position peaked at $576K in Q1 2015.
206 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2019.

Based on Glenmede Trust's 13F filing for Q2 2019, filed 13 Aug 2019.